Gene therapy manufacturing partnership to support ‘booming’ market

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	Yok46233042)
(Image: Getty/ Yok46233042)

Related tags: Gene therapy, CDMO, Manufacturing, Ema, Fda

Axovant has signed a strategic partnership agreement with the CDMO Yposkesi to support its growing gene therapy pipeline.

Through the agreement, Yposkesi, a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing, will provide Axovant Sciences access to current good manufacturing processes (cGMP) grade facilities for Adeno-Associated​ Virus (AAV) production.

Axovant will receive dedicated suite space and access to manufacturing resources for its AAV-based gene therapy programs through development and commercialization.

Alain Lamproye, CEO of Yposkesi, told us “flexible and quick access to manufacturing capacity is key in the development of early stage clinical candidates, and especially for viral vectors where a global shortage of capacity has been observed.”

Lamproye said the gene therapy manufacturing market is “booming,”​ and will continue to grow at rates ranging from 15-20%.

“The recent clinical successes in the treatment of neuromuscular diseases, as well as the advent of CAR-T cells, are all indicators triggering demand for large-scale manufacturing capacities,”​ he explained.

Additionally, the two companies will work together to establish practices in process development, technology transfer, manufacturing scale-up, quality control and assurance.

Yposkesi will expand its capacity in 2019 to support commercial production following this agreement. The company said it will increase its global footprint by 2021 through a 100,000 square-foot facility equipped with several 1,000L bioreactors.

The manufacturing processes provided through this partnership comply with both European Medicines Agency (EMA) guidelines as well as US Food and Drug Administration (FDA) requirements for Phase I-III clinical trial supplies.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Related suppliers

Follow us


View more